Netols Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Netols Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$5.21M	Sell	371,226 -32,773	-8%	-$537K	1.17%	51
2016 Q4	$7.58M	Sell	403,999 -17,106	-4%	-$291K	1.56%	31
2016 Q3	$6.95M	Buy	421,105 +49,682	+13%	+$736K	1.54%	25
2016 Q2	$4.99M	Sell	371,423 -14,227	-4%	-$208K	1.13%	56
2016 Q1	$5.9M	Buy	385,650 +4,318	+1%	+$67.7K	1.31%	44
2015 Q4	$7.57M	Buy	381,332 +1,859	+0.5%	+$35.3K	1.67%	23
2015 Q3	$6.61M	Sell	379,473 -7,998	-2%	-$163K	1.5%	33
2015 Q2	$7.83M	Sell	387,471 -7,537	-2%	-$145K	1.54%	29
2015 Q1	$6.95M	Sell	395,008 -11,192	-3%	-$191K	1.35%	44
2014 Q4	$6.61M	Buy	406,200 +10,857	+3%	+$199K	1.28%	49
2014 Q3	$8.72M	Sell	395,343 -26,902	-6%	-$551K	1.66%	14
2014 Q2	$8.5M	Buy	422,245 +15,913	+4%	+$270K	1.37%	35
2014 Q1	$7.55M	Buy	+406,332	New	+$5.59M	1.21%	53

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Netols Asset Management's AMRI Position: Q1 2017 in Review

Netols Asset Management reduced its Albany Molecular Research Inc (AMRI) stake by 8.1% in Q1 2017, selling an estimated $537K and leaving 371,226 shares worth $5.21M. The position accounts for 1.17% of the portfolio, ranked #51.

Netols Asset Management first reported a position in AMRI in Q1 2014 and has held it in 13 quarters since. The position peaked at $8.72M in Q3 2014. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

Netols Asset Management held 371,226 shares of Albany Molecular Research Inc worth $5.21M as of Q1 2017.
Netols Asset Management sold 32,773 Albany Molecular Research Inc shares in Q1 2017, an estimated $537K.
Albany Molecular Research Inc made up 1.17% of Netols Asset Management's portfolio in Q1 2017, its #51 holding.
Netols Asset Management first reported a position in Albany Molecular Research Inc in Q1 2014 and has held it in 13 quarters since.
Netols Asset Management's Albany Molecular Research Inc position peaked at $8.72M in Q3 2014.
139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Netols Asset Management's 13F filing for Q1 2017, filed 10 May 2017.